Biophytis S.A. - Asset Resilience Ratio
Biophytis S.A. (ALBPS) has an Asset Resilience Ratio of 16.07% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2024)
This chart shows how Biophytis S.A.'s Asset Resilience Ratio has changed over time. Check Biophytis S.A. strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Biophytis S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ALBPS market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €850.00K | 12.83% |
| Short-term Investments | €214.00K | 3.23% |
| Total Liquid Assets | €1.06 Million | 16.07% |
Asset Resilience Insights
- Good Liquidity Position: Biophytis S.A. maintains a healthy 16.07% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Biophytis S.A. Industry Peers by Asset Resilience Ratio
Compare Biophytis S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Akero Therapeutics Inc
NASDAQ:AKRO |
Biotechnology | 55.87% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Zealand Pharma A/S
CO:ZEAL |
Biotechnology | 63.98% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Immunitybio Inc
NASDAQ:IBRX |
Biotechnology | 38.07% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Annual Asset Resilience Ratio for Biophytis S.A. (2012–2024)
The table below shows the annual Asset Resilience Ratio data for Biophytis S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 2.75% | €190.00K ≈ $222.13K |
€6.90 Million ≈ $8.07 Million |
-22.98pp |
| 2023-12-31 | 25.74% | €3.08 Million ≈ $3.60 Million |
€11.96 Million ≈ $13.98 Million |
+0.34pp |
| 2022-12-31 | 25.39% | €5.58 Million ≈ $6.53 Million |
€21.99 Million ≈ $25.71 Million |
+2.70pp |
| 2021-12-31 | 22.69% | €8.23 Million ≈ $9.62 Million |
€36.26 Million ≈ $42.39 Million |
-32.43pp |
| 2020-12-31 | 55.13% | €15.00 Million ≈ $17.54 Million |
€27.21 Million ≈ $31.81 Million |
+52.44pp |
| 2019-12-31 | 2.69% | €475.00K ≈ $555.32K |
€17.67 Million ≈ $20.66 Million |
-43.05pp |
| 2018-12-31 | 45.74% | €10.00 Million ≈ $11.69 Million |
€21.86 Million ≈ $25.56 Million |
+9.21pp |
| 2016-12-31 | 36.53% | €3.07 Million ≈ $3.58 Million |
€8.39 Million ≈ $9.81 Million |
+36.53pp |
| 2015-12-31 | 0.00% | €367.00 ≈ $429.06 |
€13.52 Million ≈ $15.80 Million |
-24.83pp |
| 2012-12-31 | 24.84% | €300.49K ≈ $351.31K |
€1.21 Million ≈ $1.41 Million |
-- |
About Biophytis S.A.
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company's lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement w… Read more